TXG
HoldPremium Grower10x Genomics, Inc. · Healthcare · United States · $9.9B
$97.74 +4.5% · close 5 Oct · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT 10X GENOMICS, INC.
Read
10x Genomics, Inc. develops and sells integrated systems, including instruments, consumables, and software, for advanced genomic analysis, specializing in single-cell and spatial biology. The company's competitive moat is derived from its proprietary technology platforms, which provide unprecedented resolution in biological research, establishing it as a market leader in these rapidly expanding fields. 10x Genomics is a key enabler for breakthroughs in genomics and biomedical discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 516.4M | 618.7M | 610.8M | 642.8M | 7.6% | 616.9M | 620.2M | 681.0M | 2.9% |
| EPS | -1.46 | -2.18 | -1.52 | -0.35 | — | -0.59 | — | — | — |
| Shares | 115.2M | 119.1M | 122.3M | 127.7M | +10.8% | 120.2M | — | — | — |
| Debt | 95.2M | 95.4M | 82.6M | 84.4M | -3.9% | 78.8M | — | — | — |
| Equity | 805.7M | 741.0M | 710.1M | 796.3M | -0.4% | — | — | — | — |
| Op CF | -33.6M | -15.2M | 6.7M | 136.1M | 1941.6% | 127.1M | — | — | — |
| Inv CF | -350.9M | 133.5M | -32.6M | -13.4M | — | — | — | — | — |
| Fin CF | 15.8M | 13.7M | 10.9M | 6.8M | — | — | — | — | — |
Swung more than 85% of stocks we rank over the past year (73% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TXG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TXG | 10x Genomics, Inc.(you) | $9.9B | 51 | Hold |
| BRKR | Bruker Corporation | $9.1B | 50 | Hold |
| GKOS | Glaukos Corporation | $9.1B | 46 | Hold |
| PODD | Insulet Corporation | $9.5B | 60 | Hold |
| PEN | Penumbra, Inc. | $12.6B | 56 | Hold |
| BIO | Bio-Rad Laboratories, Inc. | $10.1B | 65 | Hold |
| NEOG | Neogen Corporation | $3.0B | 57 | Hold |
| ITGR | Integer Holdings Corporation | $4.3B | 71 | Buy |
| TMDX | TransMedics Group, Inc. | $3.0B | 36 | Hold |
| IRTC | iRhythm Holdings, Inc. | $3.7B | 31 | Sell |
Peer medians: ROE -31.5% · P/E 25.1x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.